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Abstract
A previous meta-analysis determined that the effects of steroids during sepsis were dose-dependent; since then, additional trials have
been published. The current analysis updates our previous analysis examining the effects of steroids during sepsis. A literature search
from 2004 to 2008 identiﬁed seven randomized controlled trials in adult patients; these were added to 14 previously identiﬁed trials.
The effects of steroids on mortality were highly variable among the 21 trials (p <0.001, I2 = 60%). In trials published before 1989, which
involved short courses of high-dose steroids, steroids increased mortality (n = 8, I2 = 14%, OR of death 1.39 (95% CI 1.04–1.86),
p 0.03). In trials published after 1997, which involved longer courses of lower-dose steroids, steroids consistently improved shock
reversal (n = 7, I2 = 0%, OR of shock reversal 1.66 [95% CI 1.25–2.20), p <0.001), but demonstrated a more heterogeneous beneﬁcial
effect on mortality (n = 12, I2 = 25%, OR of death 0.64 (95% CI 0.45–0.93), p 0.02). An inverse linear relationship between severity of
illness and the effects of steroids on mortality was identiﬁed across all trials (p 0.03) and within the subgroup of trials published after
1997 (p 0.03); steroids were harmful in less severely ill patient populations and beneﬁcial in more severely ill patient populations. There
was no effect of response to adrenocorticotrophic hormone (ACTH) stimulation testing concerning the effects of steroids and no
increase in steroid-associated adverse events. Low-dose steroids appear to improve mortality rates in patients with septic shock who
are at high risk of death; however, additional trials in this subpopulation are necessary to deﬁnitively determine the role of low-dose
steroids during sepsis.
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Introduction
Septic shock is one of the most common causes of death in
the intensive-care unit. Despite effective therapies directed
at the infecting agent (appropriate antibiotics, drainage pro-
cedures, etc.) and aggressive cardiovascular support (ﬂuid
resuscitation, vasopressors, etc.), mortality due to septic
shock remains unacceptably high, at 30–60% [1–4]. Multiple
adjunctive therapies for septic shock have been developed
and studied in clinical trials, including agents directed against
speciﬁc bacterial toxins, anti-inﬂammatory agents, and
antithrombotic agents. Despite promising preclinical results,
few therapies have demonstrated improved survival in con-
trolled clinical trials [5]. Moreover, these beneﬁcial effects
have not been consistent in conﬁrmatory trials. The varying
treatment effects of these agents can be explained, in part,
by methodological differences among the clinical trials; specif-
ically, when the trials have been compared, several factors
that may alter the efﬁcacy of these agents have been identi-
ﬁed [5–7]. For example, a meta-analysis of clinical trials of
mediator-speciﬁc anti-inﬂammatory agents in sepsis demon-
strated a signiﬁcant relationship between severity of illness
and treatment effect, characterized by beneﬁcial effects in
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severely ill patient populations and no effect, or potentially
harmful effects, in less severely ill patient populations [6].
Furthermore, a meta-analysis of trials of glucocorticoids in
the treatment of sepsis demonstrated a signiﬁcant relation-
ship between steroid dose and treatment effect, with high
doses having harmful effects and low doses having potentially
beneﬁcial effects [7]. In addition, others have reported that
the beneﬁcial effects of steroids in sepsis trials are depen-
dent on a blunted response to a corticotropin stimulation
test [8]. On the basis of these analyses, the inﬂuence of fac-
tors that might alter the efﬁcacy of a therapy in clinical sepsis
trials need to be evaluated when attempting to deﬁne the
role of an adjunctive therapy in the treatment of sepsis.
Glucocorticoids have been studied extensively as adjunc-
tive therapy in septic patients for over 40 years. Our previ-
ous meta-analysis examining the effects of steroid dose in
sepsis demonstrated that early studies (published before
1989), which involved predominantly short courses of high-
dose steroids, reported increased mortality and worsened
secondary infections [7]. In contrast, more recent trials (pub-
lished after 1997) involved longer courses of lower-dose ste-
roids and demonstrated beneﬁcial treatment effects,
including improved shock reversal and survival [7]. Since the
publication of this meta-analysis, multiple trials (including a
large, multicentre, randomized controlled trial) have been
performed. Therefore, with the current meta-analysis, we
aimed to update our previous analysis and to determine
whether severity of illness, drug dose, and response to corti-
cotropin stimulation testing inﬂuence the treatment effects
of steroids during sepsis [9].
Methods
The medical literature from January 2004 to December 2008
was searched using the following keywords in MEDLINE, EM-
BASE and the Cochrane library: ‘steroids and sepsis’, ‘ste-
roids and septic shock’, ‘glucocorticoids and sepsis’,
‘glucocorticoids and septic shock’, ‘corticosteroids and sep-
sis’, and ‘corticosteroids and septic shock’. In addition,
abstracts from national and international critical-care confer-
ences and published meta-analyses were reviewed to identify
other potentially relevant studies and outcomes not previ-
ously identiﬁed. Consistent with our previous analysis, clini-
cal trials were included if they fulﬁlled all of the following
criteria: a prospective randomized controlled trial design
comparing glucocorticoid treatment with a control group
(with or without placebo treatment), enrolment of adult
patients who met the criteria for sepsis or septic shock, and
a primary endpoint including either shock reversal or sur-
vival. Within each study, criteria for sepsis or septic shock
needed to be deﬁned and consistent with the ACCP/SCCM
consensus deﬁnitions for sepsis, severe sepsis, and septic
shock [10]. In addition, similar treatments must have been
administered to both the steroid and control groups, with
the exception of the steroid treatment regimen being investi-
gated.
Each included trial was independently reviewed by two
investigators using a standardized protocol and data collec-
tion form, with discrepancies being resolved by a third
party. Abstracted data on patient characteristics, study
characteristics, treatment interventions and treatment out-
comes were collected, including: the presence of sepsis,
severe sepsis, or septic shock; type, dose and duration of
steroid administered; incidence and severity of complica-
tions of therapy (including secondary infections, gastrointes-
tinal bleeding, and neuropathy); response to corticotropin
stimulation testing; proportion of patients with shock rever-
sal; and mortality. Trial quality was assessed by evaluating
the method of randomization, use of blinding, and with-
drawal/dropout reporting, based on the methods of Jadad
[11]. To account for the different steroid regimens used in
the trials, all doses were converted to hydrocortisone
equivalents [12].
Statistical analysis
The OR of death following treatment, as compared with
control, was estimated using a random-effects model (Com-
prehensive Meta-Analysis; Biostat Inc., Englewood, NJ, USA).
Heterogeneity across studies was assessed using a Mantel–
Haenszel derived Cochran Q statistic, and reported with an
I2-value. [13,14] As previously, trials were partitioned and
excluded when signiﬁcant heterogeneity or inﬂuence was
present, to decrease the heterogeneity within a group of
studies, and to maximize differences among groups of studies
[7]. Variables previously evaluated to explain the heterogene-
ity in the treatment effects were again explored, using meta-
regression techniques (Comprehensive Meta-analysis, SAS
v 9.2; SAS Institute, Cary, NC, USA) [7]. Potential bias was
assessed by creating a funnel plot, and formally tested using
Egger’s regression method [15]. In addition, a jack-knife sen-
sitivity analysis of the late studies was performed by sequen-
tially removing each study to detect the studies that
contributed most to the remaining heterogeneity within this
group of trials [16]. All pooled ORs of death are reported
with associated 95% CIs, using random-effects models. Signif-
icant differences in characteristics between early and late
studies were assessed using an ANOVA, when a weighted
analysis was needed, or a two-sample Wilcoxon test, when
an unweighted analysis was performed.
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Results
Study ﬂow and quality
The current literature search identiﬁed seven new prospec-
tive randomized controlled trials, published since 2003,
which met our inclusion criteria and were included in the
current analysis (Fig. 1) [17–23]. Characteristics of the 21 tri-
als included in this analysis are depicted in Table 1 [8,17–36].
All included studies were prospective randomized trials that
involved similar co-interventions in each study group, with
the exception of the steroid regimen being investigated.
Blinding, randomization schemes and patient follow-up were
adequate in most trials, with all but two studies having a Ja-
dad quality score of three or higher (Table 1) [23,31].
Among the 21 trials, three have been published only in
abstract form [23,29,35].
Effects of steroids on mortality
The effects of steroids on mortality were highly variable
among the 21 trials (p <0.001, I2 = 60%), with an overall
non-signiﬁcant effect on mortality (Fig. 2). Consistent with
our previous analysis, heterogeneity decreased when the 21
trials were partitioned into studies published before 1989
[24,25,27,30–35] and published after 1997 [8,17–23,26,28,
29,36]. As the group of trials published before 1989 was
identical to our previous analysis, they were analysed in a
similar fashion, with subsequent exclusion of a single outlier
study from subsequent analyses (Fig. 2) [33]. Similar to the
ﬁndings of our previous meta-analysis, the treatment effects
of steroids were signiﬁcantly different in trials published
before 1989 than in trials published after 1997 (p 0.001). Ste-
roids increased mortality in trials published before 1989
(n = 8, I2 = 14%, OR of death 1.39, 95% CI 1.04–1.86,
p 0.03), and decreased mortality in trials published from
1997 through 2008 (n = 12, I2 = 25%, OR of death 0.64,
95% CI 0.45–0.93, p 0.02).
Inﬂuence of steroid regimen and control mortality on the
treatment effects of steroids
As compared with the trials published before 1989, trials
published from 1997 through 2008 involved lower total
doses of steroids over a longer duration, and were more
likely to taper the steroids (p 0.007, p 0.01, and p 0.01,
respectively) (Table 2). Mean control mortality rates, indica-
tions for therapy, and percentage of enrolled patients with
shock or patients receiving vasopressors were similar
between the two groups of studies.
Meta-regression analysis of all of the trials revealed a sig-
niﬁcant direct linear relationship between steroid dose and
the OR of death (p 0.03), characterized by beneﬁcial effects
at lower doses and harmful effects at higher doses (Fig. 3). In
addition, meta-regression analysis demonstrated a signiﬁcant
inverse linear relationship between severity of illness of the
patient population (measured by control odds of death) and
the OR of death (p 0.02), indicating that, in less severely ill
patients, steroids were harmful and, as severity of illness
increased, steroids became beneﬁcial (Fig. 3). As in our pre-
vious analysis, a single overly inﬂuential trial was identiﬁed
and removed from the meta-regression analyses [25]. The
results of the current meta-regression analyses remain essen-
tially unchanged, whether the inﬂuential study is included or
excluded.
A subgroup analysis of the trials published after 1997 using
meta-regression analysis demonstrated a signiﬁcant inverse
linear relationship between severity of illness of the patient
744 Potentially relevant 
published trials review 
and abstracts reviewed: 
734 Reports of non-clinical trials or 
duplicate citation across databases 
excluded 
10 Randomized controlled
trials reviewed in detail
7 Randomized controlled
trials published after 2003
14 Randomized controlled
trials published before
2004 included in
previous meta-analysis
21 Randomized controlled
trials included in
meta-analysis
3 Randomized controlled trials 
excluded: 
2 Non-septic patient population
1 Outcomes of interest not available
FIG. 1. Study selection ﬂow diagram.
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population and the OR of death (p 0.03), similar to the rela-
tionship demonstrated among all of the trials combined
(Fig. 3). As expected, because the doses of steroids adminis-
tered in the trial published after 1997 were similar (range in
hydrocortisone equivalents: 30–420 mg over ﬁrst 24 h after
enrolment), there was no relationship between steroid dose
TABLE 1. Randomized controlled trials of steroids in sepsis
Author
Year
published Treatment
Baseline
differences
reported
Study
design
Co-interventions
reported
Endpoints available for
meta-analysisa
Jadad
score
Bennett et al. [25] 1963 Hydrocortisone 300 mg · 1,
then decreased by 50 mg/day
Yes Double-blind Antibiotics,
vasopressors
Hospital mortality,
complications of
treatment
4
Klastersky et al. [30] 1971 Betamethasone 1 mg/kg/day
for 3 days
No Double-blind Antibiotics,
vasopressors,
ﬂuids
20-day mortality,
complications of
treatment
4
Schumer [33] 1976 Dexamethasone 3 mg/kg or
methylprednisolone 30 mg/kg;
may be repeated · 1
No Double-blind Antibiotics 28-day mortality,
complications of
treatment
4
Thompson et al. [35] 1976 Methylprednisolone 30 mg/
kg · 1, and then repeated up
to three times within 24 h if
in shock
No Double-blind Antibiotics Hospital mortality,
toxicities of treatment
3
Lucas et al. [31] 1984 Dexamethasone 2 mg/kg bolus
followed by 2 mg/kg/24 h in
ﬁrst 48 h
No Open-label Antibiotics, digoxin,
ﬂuids, diuresis
14-day mortality,
complications of
treatment
1
Sprung et al. [34] 1984 Methylprednisolone 30 mg/kg
or dexamethasone 6 mg/kg;
repeat · 1 at 4 h if still in
shock
No Open-label Antibiotics,
vasopressors, ﬂuids
Hospital mortality, shock
reversal, complications of
treatment
3
Bone et al. [27] 1987 Methylprednisolone 30 mg/
kg · 4
Yes Double-blind Standard therapy 14-day mortality, shock
reversal, complications of
treatment
5
Veterans
Administration [24]
1987 Methylprednisolone 30 mg/kg
bolus followed by 5 mg/kg/h
for 9 h
Yes Double-blind Antibiotics, ﬂuids 14-day mortality,
complications of treatment
5
Luce et al. [32] 1988 Methylprednisolone 30 mg/
kg · 4 over 24 h
No Double-blind Antibiotics,
standard care
Hospital mortality, ARDS,
complications of
treatment
5
Bollaert et al. [26] 1998 Hydrocortisone 100 mg every
8 h · 5 days, and then 6-day
taper
No Double-blind Antibiotics,
vasopressors, ﬂuids
28-day mortality, shock
reversal, complications of
treatment
5
Briegel et al. [28] 1999 Hydrocortisone 100 mg · 1,
and then 0.18 mg/kg/h until
off pressors, and then 6-day
taper
No Double-blind Antibiotics,
vasopressors, ﬂuids
30-day mortality, shock
reversal, complications of
treatment
5
Chawla et al. [29,37] 1999 Hydrocortisone 100 mg every
8 h · 3 days, and then tapered
over 4 days
No Double-blind Not reported Shock reversal; 28-day
mortality, complications
of treatment
3
Yildiz et al. [36] 2002 Prednisolone 5 mg every
morning and 2.5 mg every
afternoon · 10 days
No Double-blind Antibiotics,
vasopressors, ﬂuids
28-day mortality,
complications of
treatment
5
Annane et al. [8] 2002 Hydrocortisone 50 mg every
6h + ﬂudrocortisone 50 lg
every day · 7 days
No Double-blind Antibiotics,
vasopressors, ﬂuids
28-day mortality, shock
reversal, complications of
treatment
5
Confalonieri et al. [18] 2005 Hydrocortisone 200 mg · 1,
and then 10 mg/h · 7 days
Yes Double-blind Antibiotics Shock reversal, hospital
and 60-day mortality,
complications of treatment
5
Mussack et al. [19] 2005 Hydrocortisone 100 mg · 1,
and then 0.18 mg/kg/h until
off pressors, and then 6-day
taper
No Double-blind Antibiotics,
vasopressors, ﬂuids
Shock reversal; 28-day
mortality
4
Oppert et al. [20] 2005 Hydrocortisone 50 mg · 1,
and then 0.18 mg/kg/h until
off pressors, and then 3-day
taper
No Double-blind Antibiotics,
vasopressors, ﬂuids
Shock reversal; 28-day
mortality
5
Tandan et al. [23] 2005 Low-dose steroids (regimen
not speciﬁed)
Not speciﬁed Not speciﬁed Not speciﬁed Shock reversal; 28-day
mortality
1
Rinaldi et al. [21] 2006 Hydrocortisone 12.5 mg/
h · 6 days, and then tapered
No Open-label Antibiotics, ﬂuids Hospital mortality 3
Cicarelli et al. [17] 2007 Dexamethasone 0.2 mg/kg
every 36 h · 3
Yes Double-blind Antibiotics,
vasopressors, ﬂuids
28-day mortality,
complications of
treatment
5
CORTICUS [22] 2008 Hydrocortisone 50 mg every
6 h · 5 days, and then tapered
over 6 days
No Double-blind Antibiotics,
vasopressors, ﬂuids
Shock reversal; 28-day
mortality, complications
of treatment
5
ARDS, adult respiratory distress syndrome.
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and the OR of death within the group of trials published
after 1997 (p not signiﬁcant; data not shown).
Inﬂuence of response to adrenocorticotropic hormone
(ACTH) stimulation testing on the treatment effects of
steroids
Five of the trials published after 1997 report mortality
results based on patient response to a 250-lg ACTH stimu-
lation test (Fig. 4) [8,20,22,26,36]. Four of the studies deﬁned
a non-responder according to a change in cortisol level of
<9 lg/dL from baseline [8,20,22,36]; the ﬁfth study deﬁned a
non-responder according to a change in cortisol level of
<6 lg/dL from baseline [26]. The treatment effects of ste-
roids on mortality, based on response to ACTH stimulation
testing, were similar (p 0.86), and consistent within each sub-
group and overall (non-responder, I2 = 0%; responder,
I2 = 14%; combined, I2 = 0%). Steroid therapy led to similar
non-signiﬁcant decreases in mortality in both non-responders
(OR of death 0.84, 95% CI 0.59–1.12, p 0.33) and respond-
ers (OR of death 0.83, 95% CI 0.50–1.39, p 0.49). It is of
note that there was no difference in the control mortality
rate based on response to ACTH stimulation testing (p 0.26;
non-responder control mortality 50%, 95% CI 31–69%;
responder control mortality 38%, 95% CI 19–57%).
Effects of steroids on shock reversal
Seven trials published after 1997 reported a consistent effect
of steroids on 28-day shock reversal (p 0.70, I2 = 0%), with
an overall signiﬁcant increase in shock reversal in patients
treated with steroids as compared with controls (OR of
shock reversal 1.66, 95% CI 1.25–2.20, p <0.001) (Fig. 4)
[8,19,22,23,26,28,29]. Severity of illness did not inﬂuence the
effects of steroids on shock reversal across these trials (data
not shown, p 0.43). Two trials published before 1989
reported opposite effects of high-dose steroids on shock
reversal (data not shown, p not signiﬁcant within each trial)
[27,34].
Incidence of treatment-related complications in trials
published after 1997
Several trials published after 1997 reported the incidence of
treatment-related complications. As compared with controls,
there was no increase in the incidence of secondary infections
(n = 8, I2 = 19%, OR of secondary infection 0.96, 95% CI
0.63–1.45, p 0.84) [8,17,18,22,26,28,29,36,37], gastrointestinal
bleeding (n = 8, I2 = 0%, OR of gastrointestinal bleeding 1.10,
95% CI 0.65–1.88, p 0.72) [8,17,18,22,26,28,29,36,37] or neu-
ropathy (n = 2, I2 = 0%, OR of neuropathy 0.35, 95% CI
0.08–1.55, p 0.17) with steroid therapy [18,22].
Patients (deaths), n (n) Odds ratio of death
(95% Cl)Steroid group Control group
Bennett, 1963 (25) 96 (54)
46 (24)
86 (9)
28 (22)
23 (5)
43 (33)
191 (65)
112 (23)
38 (22)
22 (7)
20 (3)
23 (6)
20 (8)
150 (82)
23 (0)
12 (3)
18 (7)
14 (11)
20 (2)
14 (7)
251 (86)
1250 (479)
663 (257)
577 (248)
587 (222)
1218 (477)
634 (220)
548 (187)
584 (257)
0.78 (0.56-1.08)
1.03 (0.62-1.73)
1.39 (1.04-1.86)
0.64 (0.45-0.93)
0.02 0.14
Steroids beneficial Steroids harmful
Odds ratio of death
1.00 7.40 55.00
98 (32)
39 (22)
86 (33)
32 (25)
25 (5)
16 (11)
190 (48)
111 (24)
37 (20)
19 (12)
20 (4)
21 (10)
20 (12)
149 (91)
23 (7)
12 (5)
23 (11)
14 (13)
20 (2)
15 (12)
248 (78)
2.65 (1.48-4.75)
0.84 (0.36-1.99)
0.19 (0.08-0.42)
1.03 (0.30-3.52)
1.11 (0.28-4.48)
1.50 (0.42-5.35)
1.53 (0.98-2.38)
0.94 (0.49-1.78)
1.17 (0.47-2.91)
0.27 (0.07-0.99)
0.71 (0.14-3.66)
0.39 (0.11-1.38)
0.44 (0.13-1.57)
0.77 (0.49-1.22)
0.05 (0.00-0.96)
0.47 (0.08-2.66)
0.69 (0.20-2.43)
0.28 (0.03-3.11)
1.00 (0.13-7.89)
0.25 (0.05-1.29)
1.14 (0.78-1.65)
Study, year (ref)
Schumer, 1976 (33)
Thompson, 1976 (35)
Sprung, 1984 (34)
VA, 1987 (24)
Bollaert, 1998 (26)
Chawla, 1999 (29,37)
Confalonieri, 2005 (18)
Tandan, 2005 (23)
Cicarelli, 2007 (17)
Corticus, 2008 (22)
All studies (n = 21, I 2 = 60%)
Pre 1989 studies without ref 33 (n = 8, I 2 = 14%)
Post 1997 studies (n = 12, I 2 = 25%)
Pre 1989 studies with ref 33 (n = 9, I 2 = 73%)
Summary
Rinaldi, 2006 (21)
Oppert, 2005 (20)
Mussack, 2005 (19)
Annane, 2002 (8)
Yildiz, 2002 (36)
Briegel, 1999 (28)
Luce, 1988 (32)
Bone, 1987 (27)
Lucas, 1984 (31)
Klastersky, 1971 (30)
FIG. 2. Effects of steroids on mortality in randomized controlled sepsis trials. The OR of death and 95% CI with steroid therapy is shown.
Analysis of all 21 trials demonstrated variability in the effects of steroids on mortality (I2 = 60%, p <0.001). As previously, studies were
partitioned into those published before 1989 and after 1997 to decrease heterogeneity. In the 12 trials published after 1997, there remained a
moderate amount of heterogeneity in the effects of steroids on mortality (I2 = 25%, p 0.20), with an overall decrease in the OR of death with
steroid therapy (p 0.02). Signiﬁcant heterogeneity remained in the treatment effects of steroids in the nine trials published before 1989
(I2 = 73%, p <0.001). Removal of a single trial that was a signiﬁcant outlier [33] decreased the heterogeneity in these trials (I2 = 14%, p 0.33). In
the remaining eight trials published before 1989, steroids signiﬁcantly increased the OR of mortality (p 0.03).
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Publication bias and sensitivity analysis in trials published
after 1997
Visual examination of a funnel plot of the trials published
after 1997 suggests potential publication bias, with a dispro-
portionately high number of the published small trials demon-
strating beneﬁcial treatment effects of steroids (Fig. 5).
Formal testing for publication bias, using Egger’s regression
method, statistically supports the presence of publication bias
in the studies published after 1997 (p 0.002). A jack-knife
sensitivity analysis revealed that eight studies increased heter-
ogeneity (I2 increased) and four studies decreased heteroge-
neity (I2 decreased) when the individual study was removed
(Fig. 5). It is of note that the two studies with largest effect
on the heterogeneity among these 12 trials (I2 = 25%) were
the largest randomized controlled trial (I2 = 0% if removed)
[22] and the small trial with the largest beneﬁcial treatment
effect of steroids (I2 = 11% if removed) [18].
Discussion
Since 2003, seven prospective randomized controlled trials
have reported the effects of low-dose steroids on either
shock reversal or mortality during sepsis. Previously, we iden-
tiﬁed ﬁve trials (published from 1997 to 2003) reporting the
effects of low-dose steroids on either shock reversal or mor-
tality during sepsis; these ﬁve trials demonstrated a consistent
beneﬁcial effect of low-dose steroids on both shock reversal
and mortality [8,26,28,29,36,37]. Combined analysis of all 12
low-dose steroid trials published after 1997 demonstrated
beneﬁcial effects of low-dose steroids during sepsis. Similar
to the ﬁndings of our previous analysis, low-dose steroids
demonstrated a consistent improvement in shock reversal
across the trials reporting this outcome. In contrast, hetero-
geneity in the effects of low-dose steroids on mortality
increased to moderate levels in the current analysis. The dif-
fering effects of steroids on mortality across the 12 low-dose
steroid trials may be explained, in part, by the inﬂuence of
severity of illness on the treatment effects of steroids. An
inverse linear relationship between severity of illness of the
studied patient population and the effects of steroids on mor-
tality was identiﬁed; low-dose steroids appear to increase
mortality or have no effect in less severely ill patient popula-
tions, and to decrease mortality in more severely ill patient
populations. Our current meta-analysis suggests that low-
dose steroid therapy may reverse shock in most patients with
septic shock, but may decrease mortality only in patients with
more severe septic shock who are at high risk of death.
TABLE 2. Characteristics of trials published before 1989 vs. after 1997
Author
Years in
which
patients
were
enrolled
Control
mortality
rate (%)
Patients
with
shock
(%)
Patients
receiving
vasopressors
(%)
Total steroid
dose (mg of
hydrocortisone
equivalents)a,b
Length of
therapyc
Steroid
taper Indication for therapy
Bennett et al. [25] 1959–1963 33 NR NR 1050 6 days Nod Severe infection
Klastersky et al. [30] NR 56 NR NR 7000 3 days No Severe infection
Thompson et al. [35] NR 78 100 NR 42 000 24 h No Shock
Lucas et al. [31] 1978–1980 20 100 NR 11 200 48 h No Shock
Sprung et al. [34] 1979–1982 69 100 93 21 700 4 h No Shock
Bone et al. [27] 1982–1985 25 38 NR 42 000 24 h No Severe sepsis
Veterans
Administration [24]
1983–1986 22 NR NR 26 250 9 h No Sepsis
Luce et al. [32] 1983–1986 54 100 44 42 000 24 h No Shock
Bollaert et al. [26] NR 63 100 100 1500 5 days Yes Vasopressor-dependent shock
Briegel et al. [28] 1993–1996 20 100 100 1209 6 days Yes Vasopressor-dependent shock
Chawla et al. [29,37] NR 48 100 100 900 3 days Yes Vasopressor-dependent shock
Yildiz et al. [36] 1997–1999 60 23 NR 300 10 days No Severe sepsis
Annane et al. [8] 1995–1999 61 100 100 1400 7 days No Vasopressor-dependent shock
Confalonieri et al. [18] 2000–2003 30 7 7 1880 7 days No Pneumonia
Mussack et al. [19] NR 42 100 100 1209 6 days Yes Vasopressor-dependent shock
Oppert et al. [20] NR 48 100 100 453 2 days Yes Vasopressor-dependent shock
Tandan et al. [23] NR 93 100 NR NR NR NR Septic shock
Rinaldi et al. [21] NR 10 0 0 1800 6 days Yes Severe sepsis
Cicarelli et al. [17] 2004–2005 80 100 100 1119 3 days No Vasopressor-dependent shock
CORTICUS [22] 2002–2005 31 100 99 1000 5 days Yes Vasopressor-dependent shock
Summary Value Weighted
mean (%)
Weighted
mean (%)
Weighted
mean (%)
Median Median (days) Rate Median
Before 1989 35 63 65 23 975 1 0/8 Shock
After 1997 44 90 89 1209 6 7/11 Vasopressor-dependent shock
NR, not reported.
aTotal possible dose of steroid that could have been received by a patient in a trial before beginning a taper; if two drugs were used in the trial, the average total dose was
used.
bDose based on a 70-kg patient.
cLength of steroid therapy before taper was begun.
dDecreasing doses of steroids over 6 days were considered to constitute a steroid treatment regimen and not a taper in the original report and all previous meta-analyses.
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Previously, we identiﬁed nine trials examining the effects
of steroids during sepsis published before 1989 [7]. Overall,
these trials demonstrated a harmful effect of steroids on
mortality after exclusion of a single outlier trial [33]. In our
previous analysis, the different effects of steroids in trials
published before 1989, as compared with trials published
after 1997, could be explained, in part, by a linear relation-
ship between steroid dose and treatment effect [7]. Our cur-
rent analysis demonstrated similar differences between the
nine trials published before 1989 and the 12 trials published
after 1997, and conﬁrmed the relationship between steroid
dose and treatment effect. In the trials published before
1989, high-dose steroids were administered to decrease the
excessive inﬂammation associated with sepsis. These earlier
trials involved signiﬁcantly shorter courses of higher-dose
steroids, which may have led to harmful immunosuppression.
In contrast, the trials published after 1997 involved longer
courses of steroids, in a dose range equivalent to the
(a)
(c)
(b)
FIG. 3. Inﬂuence of steroid dose and severity of illness on the effects of steroids on mortality. (a) There is a signiﬁcant linear relationship
between the dose of steroids administered in the ﬁrst 24 h after study enrolment and the OR of death across the steroid sepsis trials (p 0.03);
steroids decreased mortality at lower doses, and increased mortality as steroid dose increased. (b) A signiﬁcant inverse linear relationship
between the control odds of death (a measure of severity of illness) and the OR of death also exists across the steroid sepsis trials (p 0.03); ste-
roids increase mortality in patient populations with a low control odds of death (less severely ill), and decrease mortality in patient populations
with a high control odds of death (more severely ill). As in our previous analysis, a single overly inﬂuential trial with methodological differences
was identiﬁed and removed from these meta-regression analyses [25]. (c) In the subgroup of trials published after 1997 that administered only
lower-dose steroids (range in hydrocortisone equivalents: 30–420 mg over ﬁrst 24 h after enrolment), a similar signiﬁcant inverse linear relation-
ship between the control odds of death and the OR of death exists (p 0.03), suggesting that low-dose steroids increase mortality in less severely
ill patient populations and decrease mortality in more severely ill patient populations.
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amount of steroids produced by the body during a stressful
state (c. 300 mg of cortisol per day), to treat critical illness-
related corticosteroid insufﬁciency [38]. The lower doses of
steroids administered in the more recent trials do not
appear to be immunosuppressive, as evidenced by similar
rates of secondary infections in the treatment and control
groups in these trials. In addition, low-dose steroids did not
lead to higher rates of other steroid-related adverse events,
including gastrointestinal bleeding and neuropathy.
In our earlier meta-analysis, we were unable to identify a
relationship between severity of illness and treatment effects
[7]. At that time, we noted that this relationship may exist,
but may not have been identiﬁed, secondary to the inﬂuence
of drug dose, a limited range of severity of illness, or a lack
of power. In the current analysis, there was no relationship
between severity of illness and the effects of steroids on
shock reversal; however, there was a relationship between
severity of illness and the effects of steroids on mortality,
both within the group of the trials published after 1997 and
when examining all of the trials combined. The increased
power and range of severity of illness provided by the addi-
tion of the seven studies published since 2003 allowed for
the identiﬁcation of this relationship in the current analysis.
The relationship between severity of illness and treatment
effect identiﬁed in this analysis is consistent with the
reported effects of severity of illness on the treatment
effects of other adjunctive therapies for sepsis, including
mediator-speciﬁc anti-inﬂammatory agents and recombinant
activated protein C, in both preclinical and clinical trials
[6,39]. However, this relationship could not be reproduced
prospectively in an antibiotic-treated mouse pneumonia
model, which was used to investigate the effects of hydro-
cortisone over a wide range of risk of death [40].
Potential mechanisms responsible for the beneﬁcial effects
of low-dose steroids include an increase in vascular smooth
muscle sensitivity to both exogenous and endogenous vaso-
pressors, treatment of critical illness-related corticosteroid
insufﬁciency, and attenuation of dysregulated inﬂammation
and coagulation associated with sepsis [41,42]. The steroid-
associated increase in vascular smooth muscle sensitivity may
lead to improved shock reversal in patients with septic
shock, regardless of their risk of death. However, similar to
what occurs with other adjunctive therapies, the potential
anti-inﬂammatory effects of low-dose steroids may explain
their effects on mortality [6,39]. In severely ill patients who
are likely to die from sepsis, attenuation of sepsis-associated
dysregulated inﬂammation by low-dose steroids may
decrease mortality. In contrast, in septic patients for whom
the likelihood of survival is high, the potential anti-inﬂamma-
tory and immunosuppressive effects of low-dose steroids
may impair host defence mechanisms and lead to worse out-
come.
(a) (b)
FIG. 4. Effects of low-dose steroids on mortality based on response to adrenocorticotropic hormone (ACTH) stimulation testing and the effects
of steroids on shock reversal. (a) The OR of death and 95% CI with steroid therapy based on patient response to a 250-lg ACTH stimulation
test are shown for the ﬁve trials published after 1997 that reported mortality results using these subgroups [8,20,22,26,36]. The treatment
effects of steroids on mortality based on response to ACTH stimulation testing were similar (p 0.86) and consistent within both subgroups and
combined groups (non-responder, I2 = 0%; responder, I2 = 14%; combined, I2 = 0%). Low-dose steroids demonstrated similar non-signiﬁcant
decreases in mortality in both non-responders (OR of death 0.84, 95% CI 0.59–1.12, p 0.33) and responders (OR of death 0.83, 95% CI 0.50–
1.39, p 0.49) to ACTH stimulation testing. (b) The OR of 28-day shock reversal and 95% CI with steroid therapy is displayed for the seven trials
published after 1997 reporting this outcome. Low-dose steroids consistently improved 28-day shock reversal (p 0.70, I2 = 0%), with a signiﬁcant
increase in shock reversal in patients treated with steroids as compared with controls (OR of shock reversal 1.66, 95% CI 1.25–2.20, p <0.001).
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Some authors have suggested that a patient’s response to
ACTH stimulation testing should be used to determine
which septic patients should receive steroids, on the basis of
reports that only patients with a blunted response to ACTH
stimulation testing derived beneﬁt from steroid therapy [8].
However, other authors have challenged the reliability and
reproducibility of the results of ACTH stimulation testing
[43–46]. The current analysis demonstrates no difference in
the effects of steroids on mortality according to the results
of ACTH stimulation testing, and therefore does not support
the use of ACTH stimulation testing to determine which
septic patients should receive steroid therapy. This recom-
mendation is consistent with a recent consensus statement
for the use of steroids in sepsis from the American College
of Critical Care Medicine, stating that ‘‘ACTH stimulation
testing should not be used to identify those patients with
septic shock … who should receive glucocorticoids’’ [38].
Conclusions regarding the beneﬁts of low-dose steroids in
sepsis derived from this analysis are limited by the potential
inﬂuence of publication bias and by increased heterogeneity
among the trials. The funnel plot and Egger’s regression sug-
gest that a disproportionately high number of the published
small trials demonstrated beneﬁcial effects of steroids on
mortality and may be inﬂuencing the estimate of the overall
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FIG. 5 Publication bias and jackknife sensitivity analysis in the steroid trials published after 1997. (a) A funnel plot of precision versus the log
odds ratio of death with steroid therapy for the trials published after 1997 is presented; visual inspection of the plot suggests potential publica-
tion bias. There are a disproportionately high number of published small trials demonstrating beneﬁcial treatment effects of steroids (demon-
strated by the solid circles with negative log odds ratios of death on the lower left of the vertical line in the middle of the graph) than published
small trials demonstrating harmful effects of steroids (reﬂected by paucity of solid circles with positive log odds ratios of death on the lower
right of the vertical line in the middle of the graph). (b) A jackknife sensitivity analysis examining the heterogeneity of the treatment effects of
steroids on mortality in the group of trials published after 1997 is displayed. The individual trials are ordered on the X-axis by the change in I2
in when each trial is removed one at time. This analysis identiﬁed that eight studies increased heterogeneity (I2 increased; represented by the
corresponding circle with the study name to the right of the vertical line at zero) and four studies decreased heterogeneity (I2 decreased; repre-
sented by the corresponding circle with the study name to the left of the vertical line at zero) when the individual study was removed. The two
studies with the largest effects on the heterogeneity among these 12 trials are on the far left of the ﬁgure. When the CORTICUS trial [22] is
removed, the I2 goes from 25% to 0%; when the trial Confalanieri et al. [18] is removed, I2 goes from 25% to 11%. Of note, these trials repre-
sent the largest randomized controlled trial and the trial with the largest beneﬁcial treatment effect of steroids respectively. Circle size is pro-
portional to overall study size.
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effect of low-dose steroids on mortality. In addition, the
jack-knife sensitivity analysis suggests that the small trial by
Confalonieri et al. disproportionately increases the heteroge-
neity within the group of low-dose trials [18]. This trial
reported the largest decrease in mortality with steroids, and
is fundamentally different from the others, considering that
the enrolment criterion was pneumonia and not, speciﬁcally,
sepsis. Removal of this trial does not substantially change the
overall relationship between severity of illness and the effects
of steroids on mortality.
The jack-knife sensitivity analysis also suggests that
CORTICUS [22], the largest and most recent randomized
controlled trial of low-dose steroids in sepsis, disproportion-
ately increases the heterogeneity within the group of low-
dose trials. This multicentre trial is the only study to report
increased mortality with low-dose steroids during sepsis. Mul-
tiple issues surrounding the interpretation of the CORTICUS
[22] results have been raised. First, according to the authors,
this trial was terminated early, ‘‘due to a combination of slow
enrollment, termination of funding, and time expiry of the
drug’’. The early termination decreased the power of the
study to detect a treatment effect of steroids on mortality to
<35% [47]. In addition, the power of this trial was also limited
by a lower than expected control mortality rate (expected,
40%; actual, 31%). Furthermore, the slow enrolment and less
severely ill patient population may have been due to a loss of
equipoise during the study, secondary to the publication of
treatment guidelines recommending low-dose steroid therapy
for patients with vasopressor-dependent septic shock [48]. It
is possible that clinicians chose to treat more severely ill sep-
tic patients with steroids rather than allow them to partici-
pate in the randomized controlled trial; this could account
for the lower than expected control mortality rate in the
trial, the slow enrolment, and an undetectable treatment
effect. It is of note that the results of the CORTICUS trial
are consistent with the relationship between severity of ill-
ness and the effects of steroids on mortality demonstrated in
our analysis. In addition, removal of this trial does not sub-
stantially change the overall relationship between severity of
illness and the effects of steroids on mortality. Interpreted
together, these results suggest that low-dose steroids may
improve survival in severely ill septic patients and that further
clinical trials of low-dose steroids in septic patients with high
mortality rates are warranted.
Conclusions
The effects of steroids in sepsis are dependent on both ste-
roid dose and severity of illness. High-dose steroids during
sepsis increase mortality. Low-dose steroids improve shock
reversal during sepsis, independently of severity of illness;
however, the effects of low-dose steroids on mortality
appear to be dependent on severity of illness, with low-dose
steroids decreasing mortality in more severely ill patients.
Additional clinical trials with severely ill patients with refrac-
tory septic shock who require high-dose vasopressors are
necessary to deﬁnitively determine the role of low-dose ste-
roids during sepsis. Until such data are available, the decision
to administer low-dose steroid therapy to a septic patient
must be made on an individual basis, taking into account the
patient’s severity of illness and the risk of adverse events
due to therapy. ACTH stimulation testing should not be
used to determine which patients should receive steroid
therapy. The currently available data suggest that a 5–7-day
course of hydrocortisone (200–300 mg daily, either in
divided doses or as a continuous infusion), followed by a
taper over 3–5 days, may reduce mortality in patients with
septic shock who are at high risk of death (i.e. patients with
refractory septic shock requiring high-dose vasopressors).
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